Symposium 1: Pro/Con Therapeutic Drug Monitoring of Monoclonal AntiBody in Oncology |
Monday September 14, 1200-1300 (UTC)
Joseph Ciccolini, Aix Marseille Université U105, Institut Paoli Calmettes & APHM
D.J.A.R Moes, Leiden University Medical Center, The Netherlands
Etienne Chatelut, Institut Universitaire du Cancer-Toulouse, France
Jeroen J.M.A. Hendrikx, The Netherlands Cancer Institute – Amsterdam, The Netherlands
Learning Objectives: At the end of this session participants will be able to:
- Describe the current challenges and pitfalls of TDM in Oncology.
- Discuss pharmacokinetic-pharmacodynamic relationships of Mab in Onco-Hematology.
- Formulate their own opinion on this pending issue (i.e., TDM of Mab in Oncology).
D.J.A.R Moes, Leiden University Medical Center, The Netherlands
Etienne Chatelut, Institut Universitaire du Cancer-Toulouse, France
Jeroen J.M.A. Hendrikx, The Netherlands Cancer Institute – Amsterdam, The Netherlands
Learning Objectives: At the end of this session participants will be able to:
- Describe the current challenges and pitfalls of TDM in Oncology.
- Discuss pharmacokinetic-pharmacodynamic relationships of Mab in Onco-Hematology.
- Formulate their own opinion on this pending issue (i.e., TDM of Mab in Oncology).